JP2019530671A5 - - Google Patents

Download PDF

Info

Publication number
JP2019530671A5
JP2019530671A5 JP2019513333A JP2019513333A JP2019530671A5 JP 2019530671 A5 JP2019530671 A5 JP 2019530671A5 JP 2019513333 A JP2019513333 A JP 2019513333A JP 2019513333 A JP2019513333 A JP 2019513333A JP 2019530671 A5 JP2019530671 A5 JP 2019530671A5
Authority
JP
Japan
Prior art keywords
inhibitor
dash
lower alkyl
antagonist
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019513333A
Other languages
English (en)
Japanese (ja)
Other versions
JP7096598B2 (ja
JP2019530671A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/050474 external-priority patent/WO2018049027A1/en
Publication of JP2019530671A publication Critical patent/JP2019530671A/ja
Publication of JP2019530671A5 publication Critical patent/JP2019530671A5/ja
Priority to JP2022079413A priority Critical patent/JP7617640B2/ja
Application granted granted Critical
Publication of JP7096598B2 publication Critical patent/JP7096598B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019513333A 2016-09-07 2017-09-07 イムノdash阻害剤及びpge2アンタゴニストを用いた併用療法 Active JP7096598B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022079413A JP7617640B2 (ja) 2016-09-07 2022-05-13 イムノdash阻害剤及びpge2アンタゴニストを用いた併用療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662384407P 2016-09-07 2016-09-07
US201662384403P 2016-09-07 2016-09-07
US62/384,407 2016-09-07
US62/384,403 2016-09-07
US201762482750P 2017-04-07 2017-04-07
US62/482,750 2017-04-07
PCT/US2017/050474 WO2018049027A1 (en) 2016-09-07 2017-09-07 Combination therapies using immuno-dash inhibitors and pge2 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022079413A Division JP7617640B2 (ja) 2016-09-07 2022-05-13 イムノdash阻害剤及びpge2アンタゴニストを用いた併用療法

Publications (3)

Publication Number Publication Date
JP2019530671A JP2019530671A (ja) 2019-10-24
JP2019530671A5 true JP2019530671A5 (https=) 2020-10-15
JP7096598B2 JP7096598B2 (ja) 2022-07-06

Family

ID=61561557

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019513333A Active JP7096598B2 (ja) 2016-09-07 2017-09-07 イムノdash阻害剤及びpge2アンタゴニストを用いた併用療法
JP2022079413A Active JP7617640B2 (ja) 2016-09-07 2022-05-13 イムノdash阻害剤及びpge2アンタゴニストを用いた併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022079413A Active JP7617640B2 (ja) 2016-09-07 2022-05-13 イムノdash阻害剤及びpge2アンタゴニストを用いた併用療法

Country Status (7)

Country Link
US (5) US11583516B2 (https=)
EP (1) EP3509604B1 (https=)
JP (2) JP7096598B2 (https=)
KR (1) KR102557900B1 (https=)
CN (1) CN109906082A (https=)
CA (1) CA3036202A1 (https=)
WO (4) WO2018049008A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US11583516B2 (en) * 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
US11559537B2 (en) * 2017-04-07 2023-01-24 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
CN110869055B (zh) * 2017-07-20 2023-04-28 国立大学法人北海道大学 靶向pd-1/pd-l1的抑制剂与cox-2抑制剂的组合使用
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
US20210353652A1 (en) * 2018-06-04 2021-11-18 Trustees Of Tufts College Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
TWI812820B (zh) * 2018-12-10 2023-08-21 美商百歐克斯賽爾治療公司 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法
CN109706243A (zh) * 2018-12-18 2019-05-03 南通大学附属医院 Dpp9基因在制备治疗胃癌药物及其诊断试剂盒中的应用
JP7592621B2 (ja) 2019-04-02 2024-12-02 イミュネチューン・ベー・フェー 免疫刺激組成物及びその使用
US12221406B2 (en) * 2019-07-16 2025-02-11 Virginia Commonwealth University Compounds as NLRP3 inflammasome inhibitors and compositions and uses thereof
WO2021036793A1 (en) * 2019-08-23 2021-03-04 National Institute Of Biological Sciences, Beijing Pyroptosis-induced immunotherapy
CN110951672B (zh) * 2019-12-16 2021-09-24 武汉大学 一种小鼠子宫内膜上皮细胞及其3d分化培养物模型的构建方法
KR20220146458A (ko) * 2020-01-23 2022-11-01 마이오포르테 테라퓨틱스 인코포레이티드 Pgdh 억제제 및 그의 제조 및 사용 방법
US20240148736A1 (en) * 2020-12-14 2024-05-09 Saitama Medical University Combination drug for treating renal cancer and potentiator for therapeutic effects of tyrosine kinase inhibitor
GB2619249B (en) * 2021-02-26 2025-10-01 Can Therapy Inc Novel adamantyl derivative or pharmaceutically acceptable salt thereof, and use thereof
CN113337569A (zh) * 2021-05-26 2021-09-03 深圳市人民医院 一种基于诱导细胞炎性死亡的抗肿瘤药物筛选方法
AU2022408174A1 (en) * 2021-12-09 2024-06-27 Materia Therapeutics Inc. Cancer treatment using ketotifen in combination with a checkpoint inhibitor

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2756113A1 (de) 1977-12-16 1979-06-21 Thomae Gmbh Dr K Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4885367A (en) 1987-11-19 1989-12-05 Taisho Pharmaceutical Co., Ltd. Sulfonanilide compounds
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
EP0679157B1 (en) 1993-01-15 1997-11-19 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
CA2113787A1 (en) 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
DE69422306T4 (de) 1993-11-30 2000-09-07 G.D. Searle & Co., Chicago Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5475018A (en) 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
AU3201095A (en) 1994-07-27 1996-02-22 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5739166A (en) 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
JP2636819B2 (ja) 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
JP3181190B2 (ja) 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
US5596008A (en) 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
BR9607035A (pt) 1995-02-13 1997-11-04 Searle & Co Isoxazois substituidos para o tratamento de inflamação
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2223154A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
DE69633566T2 (de) 1995-07-21 2005-12-08 Savvipharm Inc. Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
DK0848703T3 (da) 1995-07-21 2001-01-02 Nycomed Austria Gmbh Derivater af benzosulfonamider som inhibitorer for enzymet cyclooxygenase II
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JPH0977664A (ja) 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−2特異的阻害剤及び抗炎症剤
US5981576A (en) 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6057319A (en) 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
US6222048B1 (en) 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
US6180651B1 (en) 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
ATE233743T1 (de) 1996-04-12 2003-03-15 Searle & Co N-((4-(5-methyl-3-phenylisoxazol-4- yl)phenyl)sulphonylpropylamid und sein natriumsalz als pro-pharmakon von cox-2 inhibitoren
SE9601939L (sv) 1996-05-22 1997-04-14 Bo Granbom Bromsanordning vid manöverdon för linjär rörelse
US5883267A (en) 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
GB9615867D0 (en) 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
IL127441A (en) 1996-07-18 2003-02-12 Merck Frosst Canada Inc Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
ATA16597A (de) 1997-02-03 1998-04-15 Nycomed Austria Gmbh Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
EP0863134A1 (en) 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
DE69810938T2 (de) 1997-04-11 2003-11-06 Grelan Pharmaceutical Co., Ltd. Pyrazolderivate und sie enthaltende cox-inhibitoren
US6127545A (en) 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6130334A (en) 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
AU8757098A (en) 1997-06-30 1999-02-10 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
CA2299300C (en) 1997-08-22 2007-04-17 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
DK1005460T3 (da) 1997-08-22 2006-07-10 Abbott Lab Inhibitorer af biosyntesen af prostaglandin-endoperoxid H-synthase
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
DK1032575T3 (da) 1997-09-05 2003-10-20 Glaxo Group Ltd 2,3-diaryl-pyrazol(1,5-b)pyridazinderivater, deres fremstilling og anvendelse som cyclooxygenase 2 (COX-2) inhibitor
US5925769A (en) 1997-09-09 1999-07-20 Ortho Pharmaceutical, Corp. Acetylenic 1,5-diarylpyrazoles as antiinflammatory agents
US6046217A (en) 1997-09-12 2000-04-04 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6140515A (en) 1997-09-24 2000-10-31 Merck & Co., Inc. Process of making 3-aryloxy, 4-aryl furan-2-ones useful as inhibitors of COX-2
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
US6080876A (en) 1997-10-29 2000-06-27 Merck & Co., Inc. Process for making phenyl heterocycles useful as COX-2 inhibitors
US6133292A (en) 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
EP2583675A1 (en) * 1998-02-02 2013-04-24 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
US20010031275A1 (en) 1998-02-09 2001-10-18 Forse R Armour Sesamol inhibitor of delta-5-desaturase activity and uses therefor
JP3256513B2 (ja) 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−2阻害剤
US5994379A (en) 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
JP2002517423A (ja) 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド シクロオキシゲナーゼ−2の多結合インヒビター
KR100295206B1 (ko) 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
TW587079B (en) 1998-09-25 2004-05-11 Almirall Prodesfarma Ag 2-phenylpyran-4-one derivatives
TR200101765T2 (tr) 1998-10-27 2002-02-21 Abbott Laboratories Prostaglandin endoperoksit H sentaz biyosentez inhibitörleri
US6077869A (en) 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
ES2234324T3 (es) 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
AU1534900A (en) 1998-11-12 2000-06-05 Analytica Ltd A method of treatment
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
ATE261444T1 (de) 1999-02-27 2004-03-15 Glaxo Group Ltd Pyrazolopyridine
GB9906714D0 (en) * 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
BRPI0011172B8 (pt) 1999-04-14 2021-05-25 Pacific Corp derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
AU771668C (en) 1999-06-16 2005-08-11 Temple University - Of The Commonwealth System Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
MXPA00006605A (es) 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
US6077868A (en) 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2
US6472416B1 (en) 1999-08-27 2002-10-29 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
US6306890B1 (en) 1999-08-30 2001-10-23 Vanderbilt University Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6083969A (en) 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6465509B2 (en) 2000-06-30 2002-10-15 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
AR030630A1 (es) 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
US6359182B1 (en) 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
KR100810468B1 (ko) 2001-10-10 2008-03-07 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1h-인돌 유도체
KR100809489B1 (ko) 2001-10-10 2008-03-03 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난4'-메탄설포닐-비페닐 유도체
WO2003037351A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors
US6555563B1 (en) 2001-11-16 2003-04-29 Medinox, Inc. Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
EP2316470A3 (en) * 2001-11-26 2011-08-24 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
US20030165588A1 (en) 2002-03-01 2003-09-04 Unigen Pharmaceuticals, Inc. Identification of free-B-ring flavonoids as potent COX-2 inhibitors
CA2768674A1 (en) 2002-09-19 2004-04-01 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
AU2005216970B2 (en) * 2004-02-23 2011-07-07 Trustees Of Tufts College Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism
KR20080000665A (ko) 2005-04-22 2008-01-02 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 디펩티딜 펩티다아제-ⅳ 억제제
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
JP5270369B2 (ja) * 2005-12-19 2013-08-21 タフツ ユニバーシティー/トラスティーズ オブ タフツ カレッジ ソフトプロテアーゼ抑制剤およびそのプロソフト型
WO2007117419A2 (en) 2006-03-31 2007-10-18 Dara Biosciences, Inc. Methods and compositions relating to post-prolyl cleaving enzyme inhibitors
WO2007123686A2 (en) 2006-03-31 2007-11-01 Point Therapeutics, Inc. Dpp inhibitors and uses thereof
WO2007127204A2 (en) 2006-04-24 2007-11-08 Dara Biosciences, Inc. Methods and compositions relating to immunostimulation
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Pd−1アンタゴニストおよび感染性疾患を処置するための方法
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille Pd−1抗体およびpd−l1抗体ならびにその使用
MX2011009852A (es) * 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US8518945B2 (en) * 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013078059A1 (en) * 2011-11-22 2013-05-30 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
WO2014022636A1 (en) * 2012-08-02 2014-02-06 Trustees Of Tufts College Broad spectrum inhibitors of the post proline cleaving enzymes for treatment of hepatitis c virus infections
CN104003922A (zh) 2013-02-27 2014-08-27 中国药科大学 取代吡咯烷类衍生物及其制备方法和在医药上的用途
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US11583516B2 (en) 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
WO2018187698A2 (en) 2017-04-07 2018-10-11 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists
US11559537B2 (en) 2017-04-07 2023-01-24 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
US20210353652A1 (en) 2018-06-04 2021-11-18 Trustees Of Tufts College Tumor microenvironment-activated drug-binder conjugates, and uses related thereto

Similar Documents

Publication Publication Date Title
JP2019530671A5 (https=)
ES2902360T3 (es) Inhibidores de PD-1/PD-L1
JP7783870B2 (ja) キナーゼ阻害剤の結晶性形態及び塩形態
JP7208225B2 (ja) 抗癌剤としての環状ジヌクレオチド
CA3101640A1 (en) Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
JP2016505586A5 (https=)
JP2019532657A5 (https=)
CA3085424A1 (en) Combination drug including tlr7 agonist
JP2013500304A5 (https=)
US20240065987A1 (en) Anti-cancer activity of adamantane derivatives
ES3008963T3 (en) Crystalline salt forms of a kinase inhibitor
RU2009144538A (ru) Новые циклические пептидные соединения
JP2011518168A5 (https=)
WO2019076269A1 (zh) 甲羟戊酸通路抑制剂及其药物组合物
US20250368606A1 (en) Crystalline forms and salt forms of a kinase inhibitor
EP4292658A2 (en) Alkynyl nucleoside analogs as inhibitors of human rhinovirus
HK40104785A (en) Alkynyl nucleoside analogs as inhibitors of human rhinovirus
WO2021132550A1 (ja) 術後補助療法剤
HK40061293A (en) Crystalline forms and salt forms of a kinase inhibitor
TW200526201A (en) Treating bone-related disorders with selective androgen receptor modulators